Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2013

01-07-2013 | Original Article

The role of chemoradiotherapy in patients with unresectable T4 breast tumors

Authors: Kumiko Karasawa, Mitsue Saito, Hisako Hirowatari, Hiromi Izawa, Tomohiko Furuya, Shuichi Ozawa, Kana Ito, Takahisa Suzuki, Norio Mitsuhashi

Published in: Breast Cancer | Issue 3/2013

Login to get access

Abstract

Purpose

Unresectable T4 tumors of the breast are usually treated with systemic therapies, while the role of local therapies remains debatable. This study aims to evaluate the effectiveness of chemoradiotherapy as a part of T4 breast cancer treatment, and to assess the role of local radiotherapies in patients with unresectable T4 breast tumors.

Materials/methods

Between February 1998 and June 2010, 39 unresectable T4 breast tumors were treated with chemoradiotherapy at our institutes. Clinical stages included stage IIIB (n = 15), stage IIIC (n = 3), and stage IV (n = 21). Twenty-one cases had undergone previous systemic therapies, whereas the remaining 18 cases reported no history of previous treatment. Radiation doses of 59–66 Gy (median 60 Gy) were administered to the breast in addition to concurrent chemotherapies. Acute adverse effects were assessed on a weekly basis during treatment to 2 weeks after completion of treatment, and were scored by the Common Terminology Criteria for Adverse Events v3.0. Treatment response was assessed at 1 month after completion of chemoradiotherapy. Statistical analysis of survival was calculated using the Kaplan–Meier method.

Results

Chemoradiotherapy was completed in all cases. Greater than grade 3 hematological toxicities were observed with regard to lymphocytes (33%), platelets (8%), neutrophils (3%), and hemoglobin (3%). Greater than grade 3 nonhematologic toxicities included chemoradiation dermatitis (23%) and pneumonitis (5%). Sixteen T4 tumors (41%) achieved complete response, whereas 23 (59%) achieved partial response. All patients were treated with chemotherapy and/or endocrine therapy following chemoradiotherapy. The median follow-up period was 20 months (range 3–96 months). Nineteen patients died because of progressive breast cancer. Infield recurrence or relapse was observed in 11 cases during the course of treatment, but only 3 cases were symptomatic. The 2-year overall local control rate was 73.6%, and the survival rate was 65.9%.

Conclusion

Chemoradiotherapy represents a viable option for local treatment of unresectable T4 breast tumors.
Literature
1.
2.
Bonner JA, Graces YI, Buchsbaum DJ. Interaction of chemotherapy and radiotherapy, chap 4. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 2nd ed. Philadelphia: Churchill Livingstone; 2007. p. 75–98.
3.
Milas L, Cox JD. Principles of combining radiation therapy and chemotherapy, chap 4. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 9th ed. Philadelphia: Mosby; 2009. p. 102–17.
4.
Formenti SC, Volm M. Part III clinical applications, 12 combined modality therapy in locally advancer breast cancer. In: Choy H, editor. Chemoradiation in cancer therapy. Totowa: Humana; 2003. p. 237–51.
5.
Choi S, Thames HD, Buchholz TA. Clinical part, 17 integration of radiation therapy and systemic therapy for breast cancer. In: Brown JM, Mehta MP, Nieder C, editors. Multimodal concepts for integration of cytotoxic drugs and radiation therapy. Heidelberg: Springer; 2006. p. 251–66.CrossRef
6.
Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, Saavedra-Perez D, Morales-Barrera R, Bargallo-Rocha E, et al. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiat Oncol. 2009;11(4):24.CrossRef
7.
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011;29:1014–21.CrossRefPubMed
8.
Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, et al. Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)]. Oncology. 2010;78:302–8.CrossRefPubMed
9.
Schaake-Koning C, van der Linden EH, Hart G, Engelsman E. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys. 1985;11(10):1759–63.CrossRefPubMed
10.
Rubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol. 1989;25(4):667–78.CrossRefPubMed
11.
Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in Hela and SQ20B cells. Cancer Res. 1996;56:1842–50.PubMed
12.
Choy H. Combining taxanes with radiation for solid tumors. Int J Cancer. 2000;9:113–27.CrossRef
13.
Karasawa K, Katsui K, Seki K, Kohno M, Hanyu N, Nasu S, et al. Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer. 2003;10:268–74.CrossRefPubMed
14.
Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res. 1999;5:4149–98.
15.
Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice a week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys. 1999;43:107–14.CrossRefPubMed
16.
Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol. 2001;18:599–606.PubMed
17.
Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948–53.PubMed
18.
Hirowatari H, Karasawa K, Izawa H, Ito K, Sasai K, Furuya T, et al. Full dose capecitabine with local radiotherapy is one of the treatment options for inoperable T4 breast cancer. Jpn J Radiol. 2011;29(3):222–5.CrossRefPubMed
19.
Gaui MF, Amorim G, Arcuri RA, Pereira G, Moreira D, Djahjah C, et al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol. 2007;30:78–81.CrossRefPubMed
20.
Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 1988;6(2):261–9.PubMed
21.
Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22(20):4067–74.CrossRefPubMed
22.
Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys. 2004;59(4):1062–73.CrossRefPubMed
23.
Rouëssé J, de la Lande B, Bertheault-Cvitkovic F, Serin D, Graïc Y, Combe M, Centre René Huguenin Breast Cancer Group, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006;64(4):1072–80.CrossRefPubMed
24.
Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys. 2000;48(2):393–7.CrossRefPubMed
25.
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003;21(5):864–70.CrossRefPubMed
26.
Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61(4):1045–53.CrossRefPubMed
27.
Koukourakis MI, Manavis J, Simopoulos C, Liberis V, Giatromanolaki A, Sivridis E. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicin, and docetaxel in c-erbB-2-positive breast cancer. Am J Clin Oncol. 2005;28(5):495–500.CrossRefPubMed
28.
Genet D, Lejeune C, Bonnier P, Aubard Y, Venat-Bouvet L, Adjadj DJ, et al. Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up. Br J Cancer. 2007;97(7):883–7.PubMed
29.
Shanta V, Swaminathan R, Rama R, Radhika R. Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys. 2008;70(1):51–8.CrossRefPubMed
Metadata
Title
The role of chemoradiotherapy in patients with unresectable T4 breast tumors
Authors
Kumiko Karasawa
Mitsue Saito
Hisako Hirowatari
Hiromi Izawa
Tomohiko Furuya
Shuichi Ozawa
Kana Ito
Takahisa Suzuki
Norio Mitsuhashi
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0336-3

Other articles of this Issue 3/2013

Breast Cancer 3/2013 Go to the issue

Author’s reply

Reply to Ozkan et al.: a role of elastography using maximum fat-to-lesion ratio for the diagnosis of breast lesions

Review Article

Animal model for mammary tumor growth in the bone microenvironment

Original Article

The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone

Letter to the Editor

Measuring of the maximum fat lesion ratio

Original Article

Impact of aggregate of risk factors for isolated locoregional failure in breast cancer patients treated with mastectomy without radiotherapy

Original Article

Influence of the in situ component in 389 infiltrating ductal breast carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits